Synta Pharmaceuticals, Inc. (SNTA) Tops Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. PLTR
5. META
6. JNJ
7. CSCO
8. KTOS
9. NVDA
10. QQQ

Go back to Synta Pharmaceuticals, Inc. (SNTA) Tops Q1 EPS by 1c

Roth Still Positive on Synta (SNTA) Following Q1 Results; Adjusts Certain Estimates

May 8, 2014 3:33 PM EDT

Roth is adjusting estimates on Synta Pharmaceuticals Corp. (Nasdaq: SNTA) following the company's Q1 report. The firm maintains its Buy rating and $27 target price on the company.

Analyst Joseph Pantginis said, We are encouraged that the GALAXY-1 results show separation of the Kaplan-Meier curves, demonstrating favorable overall survival for chemosensitive patients on ganetespib + docetaxel versus docetaxel alone ... We believe these results bode well for and confirm the choice of... More

Synta Pharma (SNTA) Enters $40M At-The-Market Common Sales Agreement

May 8, 2014 6:52 AM EDT

Synta Pharmaceuticals, Inc. (NASDAQ: SNTA) filed a registration with the U.S. SEC to sell, from time to time, up to $40 million of its common stock. With the filing, the company said:

We have entered into an at the market issuance... More